The USFDA conducted the good manufacturing practices (GMP) inspection at the facility from April 16, 2025, to April 24, 2025. On April 28, when the company had informed the stock exchanges of the conclusion of the USFDA inspection, it said the subsidiary had received one inspectional observation inForm 483 and there was no data integrity observation.
Last week,
Marksans Pharma’s UK-based subsidiary, Relonchem Ltd, eceived marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency for Oxybutynin hydrochloride oral solution. Oxybutynin hydrochloride is commonly used for the treatment of symptoms of overactive bladder, such as frequent or urgent urination and incontinence.
The pharma company reported a 15.6% increase in its consolidated net profit in the fourth quarter of the financial year 2025 at ₹90.5 crore from ₹78 crore in the previous year. Its revenue increased 26.5% in the March quarter to ₹708.5 crore from ₹560 crore in the year-ago period.
Shares of Marksans Pharma gained nearly 4.5% to hit an intraday high of ₹263.85 apiece on Monday, June 30. The stock was up 2.5% at ₹258.85 apiece at 1.55 pm. The stock has declined 15% this year, so far.
Also Read: HDFC Life, SBI Life shares are already having their second-best calendar year since listing
(Edited by : Shloka Badkar)
